摘要
目的 比较单次、多次表阿霉素和丝裂霉素、BCG膀胱腔内灌注预防浅表性膀胱移行细胞癌术后复发的作用。 方法 前瞻性随机对照研究 ,12 3例患者分为 4组 ,A组在术后 6h内表阿霉素 80mg单次灌注 ,B组、C组和D组分别于术后 2周内表阿霉素 4 0mg、丝裂霉素 2 0mg、BCG12 0mg多次灌注 ,观察术后复发率和无肿瘤间期及副作用发生情况。 结果 随访期 10～ 2 5个月 ,平均 18.6个月。A组复发率 18.8%、B组 14 .7%、C组 2 0 .7%、D组 17.9%。各组之间复发率及Ka plan Meier无肿瘤间期分析显示差异均无显著性意义 (P >0 .0 5 ) ,BCG组副作用明显高于其他 3组(P <0 .0 5 )。 结论 表阿霉素单次膀胱腔内灌注对预防早期、分化良好的初发浅表性膀胱移行细胞癌术后复发效果可靠 ,副作用发生率低 ,且费用低廉。
Objective To compare the value of single-dose of epirubicin and multiple instillations of epirubicin,mitomycin C,BCG into bladder for the postoperative prophylaxis of superficial bladder tumors. Methods In this prospective randomized controlled study,123 patients were assigned to 4 groups.The patients in group A received a single-dose instillation of 80 mg epirubicin immediately after operation within 6 hours.Those in group B received 40 mg epirubicin;those in group C received 20 mg mitomycin C and those in group D received 150 mg BCG 2 weeks after operation and the instillations were repeated for 6 weeks and thereafter monthly to 1 year. Results The recurrence rates were not significantly different among the 4 groups,with the rates of groups A,B,C and D being 18.8%(6/32),14.7%(5/34),20.7% (6/29) and 17.9%(5/28),respectively (χ 2, P >0.05).Kaplan-Meier analysis of disease free interval for the 4 groups showed no significant difference (log rank test, P >0.05).Side effects of group D were greater than other groups(χ 2, P <0.05). Conclusions For primary,well differentiated,early stage superficial bladder tumor,single-dose immediate intravesical instillation of epirubicin is effective for prophylaxis of tumor recurrence,with the advantage of being more cost-effective and less side effects.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2003年第7期454-456,共3页
Chinese Journal of Urology
